ArticleInfection2026
Multidisciplinary management and outcomes of abdominal vascular graft and endograft infections: a retrospective cohort study.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the multidisciplinary management and outcomes of patients with vascular graft and endograft infections of the abdominal aorta (aVGEI) in Eastern Denmark.
methodsRetrospective cohort study of aVGEI patients between 1st July 2022 and 30th June 2025. Diagnosis and management were based on a multidisciplinary team (MDT) conference. The primary outcome was 90-day mortality. Secondary outcomes included one-year mortality, cure, remission, treatment failure, and re-hospitalization.
resultsIn 35 aVGEI patients, the median age was 73 years (IQR 69.5-79 years), and the median Charlson Comorbidity Index score was 5 (IQR 3-6). The Management of Aortic Graft Infection Collaboration (MAGIC) criteria were fulfilled in 27 cases (77%, 'MAGIC positive aVGEI'). The remaining eight cases (23%) were based on conference consensus, often supported by positive PET-CT findings (n = 4/8). The most frequent monomicrobial infections were Staphylococcus aureus (n = 5/35, 14.3%) and coagulase-negative staphylococci (n = 4/35, 11.4%). Polymicrobial infections occurred in nine patients (25.7%). Five aVGEI patients were treated surgically (14.3%). The 90-day mortality was 8.6% (n = 3/35, 95%CI 1.8-3.1%); 4.2% among 'MAGIC positive aVGEI' patients (n = 1/24), 12.5% among those diagnosed on conference consensus (n = 1/8), and 33.3% among patients with an aortoenteric fistula (AEF) (n = 1/3). Among aVGEI patients with complete follow-up, cure was achieved in 31.8% (n = 7/22, 95%CI 13.9-4.9%), but none of the three patients with AEF.
conclusionWe report low short-term mortality and a cure rate of over 30% within a cohort of predominantly conservatively managed patients discussed at an MDT conference. These outcomes may reflect the benefits of individualized treatment decisions based on careful patient evaluation during MDT meetings as well as survivor bias.
Indexed as
Identifiers
42455267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.